Details of the Drug Combination

General Information of Drug Combination (ID: DC3ZHAA)

Drug Combination Name
Leuprolide Medroxyprogesterone
Indication
Disease Entry Status REF
Cognitive Impairment Phase 1 [1]
Component Drugs Leuprolide   DM5XPIJ Medroxyprogesterone   DMBGWPH
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Leuprolide
Disease Entry ICD 11 Status REF
Plasma cell myeloma 2A83.1 Approved [2]
Prostate cancer 2C82.0 Approved [3]
Endometriosis GA10 Investigative [2]
Leuprolide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Leutinizing-hormone-releasing hormone (GNRH1) TT0ID4A GON1_HUMAN Activator [5]
------------------------------------------------------------------------------------
Leuprolide Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Thyroxine-binding globulin (SERPINA7) OTUYVTSU THBG_HUMAN Increases ADR [6]
Protein bric-a-brac 2 (bab2) OTNNK0KI BAB2_DROME Increases ADR [6]
------------------------------------------------------------------------------------
Indication(s) of Medroxyprogesterone
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [4]
Medroxyprogesterone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Progesterone receptor (PGR) TTUV8G9 PRGR_HUMAN Agonist [7]
------------------------------------------------------------------------------------
Medroxyprogesterone Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Medroxyprogesterone Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Membrane progestin receptor alpha (mpra) OTEUBPKL MPRA_CYNNE Increases ADR [6]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02122198) Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
2 Leuprolide FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1175).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008 Dec;28(12):1511-22.
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
8 Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug Metab Dispos. 2008 Nov;36(11):2292-8.